Browse Category

NASDAQ:HOLX News 21 October 2025 - 23 October 2025

Blackstone (BX) Shines With Big Q3 Beat & $18B Hologic Deal – But Why Are Shares Falling?

Blackstone (BX) Shines With Big Q3 Beat & $18B Hologic Deal – But Why Are Shares Falling?

Q3 Earnings and Market Reaction Blackstone’s latest results (for the quarter ended Sept. 30) painted a mixed picture. The firm reported distributable earnings of $1.889 billion ($1.52 per share), up 48% from a year ago and well above the $1.23 forecast reuters.com. (Distributable earnings roughly measure cash profits available for dividends.) However, on a GAAP basis net income dropped to $624.9 million ($0.80/share) from $780.8 million last year, and total revenue slid about 15.7% year-over-year ts2.tech. Investors focused on the earnings miss and slowing revenue, which partly offset the beat on cash profit. As a result, BX shares dipped about 1% intraday on Oct. 23,
Blackstone & TPG in $18B Hologic Takeover Shock – Women’s Health Stock Skyrockets

Blackstone & TPG in $18B Hologic Takeover Shock – Women’s Health Stock Skyrockets

Deal Details and Company Background Hologic (NYSE: HOLX) is a Marlborough, MA–based medical technology firm focused on women’s health. Its products include mammography and breast biopsy systems, cervical cancer tests, surgical equipment (notably after its acquisition of Gynesonics), and lab diagnostics including molecular tests for Covid-19 bostonglobe.com. The Blackstone/TPG consortium will buy all outstanding Hologic shares for $76 cash plus a $3 CVR (contingent on hitting revenue goals in 2026–27 for the breast health business) marketscreener.com. This values the deal at $79 per share maximum and around $18.3 billion total enterprise value marketscreener.com. The purchase price represents a roughly 46%
Go toTop